Cytogenetic, Molecular and Cellular Biology Studies in Metastatic Melanoma Patients, Ancillary

Closed

Phase

Published

Abbreviated Title

Ancillary to SWOG-Coordinated Melanoma Trials

Activated

11/15/1996

Closed

12/15/2005

Participants

NCORP, Members, Medical Oncologists, Pathologists, ECOG

Research committees

Melanoma

Eligibility Criteria Expand/Collapse

For pts previously enrolled to and eligible for a Southwest Oncology Group-coordinated melanoma trial and about to undergo biopsy/surgery for regional lymph node or disseminated metastatic disease, OR pts must have metastatic melanoma and must be planning to be registered to a Southwest Oncology Group-coordinated melanoma trial OR for pts participating in the SWOG-9035 FISH analysis; Pts registered to SWOG-8393, SWOG-8593, SWOG-9111, SWOG-9512, E3695 are NOT eligible; Pts previously registered to SWOG-9431 need/must NOT register for subsequent specimen submissions; minimum requirements are: peripheral blood and either paraffin-embedded block of tissue sample or 5 unstained slides (SWOG-9430), paraffin-embedded tumor block or 5 micron section tissue samples (SWOG-9035), fresh tissue sent for cytogenetics and tumor banking, either paraffin-embedded block of tissue sample or 5 unstained slides, peripheral blood and fresh tumor specimen for cytogenetics (other).

Publication Information Expand/Collapse

2008

Detection of copy number alterations in malignant melanoma by both a panel of 16 DNA FISH probes and array comparative genomic hybridization: a Southwest Oncology Group study (S9431) [PMID 18483359]

SR Moore;DL Persons;JA Sosman;D Bobadilla;V Bedell;DD Smith;SR Wolman;RJ Tuthill;J Moon;VK Sondak;ML Slovak Clinical Cancer Research 14(10):2927-2935

2002

Targeting multiple genetic aberrations in isolated tumor cells by spectral fluorescence in situ hybridization

ML Slovak;F Zhang;L Tcheurekdjian;D Bobadilla;V Bedell;DA Arber;DL Persons;JA Sosman;JL Murata-Collins Cancer Detection and Prevention 26:171-179

Other Clinical Trials

SWOG Clinical Trial Number

S2000

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases

Research Committee(s)

Melanoma

Activated

09/23/2020

Accrual

91%

Open

Phase

SWOG Clinical Trial Number

CTSU/EA6174

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

Research Committee(s)

Melanoma

Activated

10/01/2018

Open

Phase

SWOG Clinical Trial Number

CTSU/EA6141

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Research Committee(s)

Melanoma

Activated

09/10/2015

Open

Phase